Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

NCT02892123 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-expressing Cancers

Interventions

DRUG: ZW25 (Zanidatamab)
DRUG: Paclitaxel
DRUG: Capecitabine
DRUG: Vinorelbine
DRUG: Tucatinib
DRUG: Tucatinib

Sponsor

Jazz Pharmaceuticals